United States Patent 7,504,095 (Scope & Claims): What It Covers, Who Owns It, and How Broad the MoCo-Deficiency Patent Estate Is
Executive summary: U.S. Patent 7,504,095 claims (1) a therapeutic composition and (2) a treatment method for human molybdenum cofactor (MoCo) deficiency and diseases traceable to corrupted MoCo synthesis, where the composition includes precursor Z plus a pharmaceutically acceptable carrier. Scope centers on the identity of “precursor Z” (defined by a chemical structure in the patent) and the intended clinical use tied to MoCo deficiency due to corrupted synthesis. The estate’s practical strength depends on how narrowly “precursor Z” is defined structurally, and whether later patents (formulations, salts, dosing regimens, manufacturing intermediates, or additional MoCo-related precursors) broaden or overlap coverage.
Because the chemical identity of “precursor Z” (structure, IUPAC/name, and stereochemical specifics) and the patent’s specification-driven claim construction are not provided in the prompt, a complete, claim-by-claim legal scope mapping to specific compounds cannot be produced. Under the operating constraints, no partial/inaccurate scope assertions follow.
What does US Patent 7,504,095 claim for molybdenum cofactor deficiency precursor Z therapy?
Claim set overview (from the provided text):
- Claim 1 (composition):
A therapeutic composition for treatment of human molybdenum cofactor deficiency and associated diseases traced to corrupted molybdenum cofactor synthesis, comprising:
- precursor Z, defined by a specific chemical structure (not reproduced in the prompt), and
- a pharmaceutically acceptable carrier.
- Claim 2 (method):
A method for treatment of the same patient population by administering a therapeutically effective amount of the composition of claim 1.
Immediate scope implications:
- Claim 1 is a composition claim with:
- an indication (MoCo deficiency and associated diseases),
- a causation qualifier (“directly or indirectly traced back to a corrupted molybdenum cofactor synthesis”), and
- a structural limitation on the therapeutic component (precursor Z).
- Claim 2 is a use/admin method tied to administering the claim 1 composition for the same indication.
What is the likely meaning of “precursor Z” in claim 1?
Claim 1 binds infringement to the presence of precursor Z having the exact chemical structure shown in the patent. Without the structure details, the only defensible statement is structural: precursor Z is the essential active-defined element of the claim. The carrier may be broad (“pharmaceutically acceptable”), which usually creates more latitude on excipients, dosage forms, and delivery vehicles, subject to the specification’s description and any dependent claims not provided.
How do the “corrupted molybdenum cofactor synthesis” qualifiers limit coverage?
The claim’s indication is not simply “MoCo deficiency.” It is MoCo deficiency and associated diseases that are traceable to corrupted MoCo synthesis. That language likely functions as:
- a patient selection limitation (the disease etiology must relate to MoCo biosynthesis corruption), and
- a causal nexus requirement that can narrow arguments that target broader MoCo-related conditions.
However, exact limiting force depends on claim construction grounded in the patent’s specification, which is not available here.
How broad is claim 1’s “pharmaceutically acceptable carrier” limitation for formulation coverage?
Direct answer from claim language: Claim 1 covers any formulation where:
- the therapeutic agent includes the claimed precursor Z, and
- the carrier is any pharmaceutically acceptable carrier.
Practical breadth (what this tends to cover):
- vehicles for oral, parenteral, or topical delivery are commonly considered “pharmaceutically acceptable carriers,” but
- the real commercial scope depends on whether the patent’s examples and working embodiments include those dosage forms and whether the specification discloses how precursor Z is stabilized, solubilized, or administered.
What cannot be asserted from the prompt: whether claim 1 implicitly limits to specific dosage forms (e.g., injectable solutions) or specific salt forms of precursor Z.
What is the infringement risk for companies using alternative MoCo precursors or analogs?
Composition infringement risk:
To infringe claim 1, an accused product must include precursor Z with the claimed structure plus a pharmaceutically acceptable carrier.
- If an alternative MoCo precursor has a different structure than the patented “precursor Z,” it falls outside the provided claim set as written.
- If an alternative is a prodrug/derivative that converts into precursor Z, infringement may hinge on:
- whether the composition itself contains precursor Z (or an equivalent) and
- claim construction on terms like “precursor Z” and whether the patent doctrine of equivalents or prosecution history estoppel arguments exist in the record.
Method infringement risk (claim 2):
A method of treatment using a non-identical compound generally avoids claim 2 if the administered therapeutic does not meet claim 1’s composition limitations. If the method uses a composition that meets claim 1, risk follows.
No landscape claimouts possible here: Without the list of related patents and litigation outcomes, no specific “who is at risk” mapping can be produced.
When does US 7,504,095 lose exclusivity in the US? (Patent expiration timing)
Answer cannot be completed from the prompt.
A patent’s expiration requires at least:
- the filing date (or priority date) and
- whether any terminal disclaimer or adjustment exists (and PTA/extension events).
The prompt provides neither filing/priority date nor maintenance/adjustment details. Under the constraints, no timeline can be stated.
Is US 7,504,095 Orange Book-listed for generics or is it only relevant to biologics?
Cannot be determined from the prompt.
Orange Book status requires:
- the drug product’s NDA/BLA mapping,
- listing of the patent to specific FDA application(s),
- Orange Book data about “active ingredient(s)” and “dosage form(s).”
The prompt provides only the patent claims, not the drug product or FDA application identifier. No Orange Book conclusion can be made.
What method-of-use and composition claim overlap exists between US 7,504,095 and follow-on patents?
What can be derived from the claim pair provided:
- Claim 2 depends on claim 1’s composition and covers administration.
- Follow-on coverage commonly appears in estates via:
- different dosage forms (e.g., lyophilized vs. liquid),
- different salt forms of precursor Z,
- different routes of administration,
- dosing regimens and patient subgroups,
- and manufacturing or intermediate claims.
What cannot be produced here: a quantified overlap map of later patents, because no other patent numbers, assignees, or documents are provided.
How strong is the patent estate implied by only claim 1 and claim 2?
Strength drivers that are visible in the claim text:
- Structural limitation on precursor Z: narrows coverage to compositions containing that exact defined chemical.
- Use limitation on MoCo deficiency due to corrupted synthesis: narrows clinical applicability.
- Broad carrier language: carrier flexibility can preserve enforceability across multiple formulations, if precursor Z is used.
Strength drivers not provable from the prompt:
- whether the specification supports broad interpretation of precursor Z or only a narrow subset,
- whether prosecution history limits claim scope,
- and whether there are dependent claims that add further coverage (e.g., salts, dose ranges, specific routes).
A reliable “strength scoring” across the US landscape is not feasible without the rest of the claims and the patent’s prosecution and family data.
What patent litigation outcomes would matter for claim 1 and claim 2 enforcement?
General relevance (without making factual assertions):
- If litigation targets infringement of claim 1, defenses typically focus on:
- whether the accused product contains the claimed precursor Z structure,
- whether formulation differences change scope (salt/prodrug questions),
- and whether the intended patient population fits the “corrupted MoCo synthesis” qualifier.
- If litigation targets claim 2, key issues become:
- whether the administered product matches claim 1 and
- whether the claimed method is actually practiced in the relevant patient population.
No docket-level mapping possible: no court case, parties, or stipulations are provided.
Which downstream product profiles could design around US 7,504,095?
Design-around vectors implied by the claim structure:
- Replace the active entity: use a non-identical precursor (not precursor Z).
- Remove the structural match: use an analog or modified precursor with a different chemical structure.
- Change the claimed use: if a competitor could avoid “treatment of MoCo deficiency… traced to corrupted MoCo synthesis” (factually and operationally), method claim exposure can drop.
Cannot be stated with confidence: whether changing patient labeling or practice patterns is legally sufficient, because that depends on actual indications, training, prescribing, and evidence.
Key takeaways
- US 7,504,095 is centered on precursor Z plus a pharmaceutically acceptable carrier (composition claim) and administration of that composition to treat MoCo deficiency due to corrupted MoCo synthesis (method claim).
- The claim’s enforceability is likely driven by how precisely precursor Z’s chemical structure is defined and how broadly the patent specification and prosecution history treat that definition.
- Formulation flexibility may exist through the generic “carrier” language, but only for products that still include the patented precursor Z.
- A complete expiration/exclusivity timeline, Orange Book status, claim charting, and landscape mapping cannot be produced from the prompt alone.
FAQs
-
What elements must an accused product have to infringe US 7,504,095 claim 1?
It must include precursor Z with the claimed structure and a pharmaceutically acceptable carrier, for treatment of MoCo deficiency tied to corrupted MoCo synthesis.
-
Can a competitor avoid claim 2 by changing the dosing schedule while using the same precursor Z composition?
Claim 2 as provided covers administering a therapeutically effective amount of the claim 1 composition; dosing schedule avoidance would depend on whether the patent includes dosing-regimen limitations in additional claims not provided here.
-
Do salts or prodrugs of precursor Z automatically fall within claim 1?
That depends on claim construction and whether the specification defines/relates such derivatives to “precursor Z.” The provided prompt does not include those details.
-
How does the “corrupted molybdenum cofactor synthesis” qualifier affect enforcement?
It narrows coverage to diseases traceable to corrupted MoCo synthesis, which can be used to challenge patient-population fit.
-
What information is required to determine the US expiration date of US 7,504,095?
Filing/priority date and any patent term adjustments or disclaimers, none of which are provided in the prompt.
References (APA)
- United States Patent and Trademark Office. (n.d.). U.S. Patent 7,504,095 (claims excerpt as provided).
